Who are Vehicle to AGN-199201's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aprepitant plus Ondansetron, Akynzeo solution, Ramosetron, Aprepitant, Dexamethasone, EMEND, Fosaprepitant for Injection, Dexamethasone, Ondansetron, Aprepitant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vehicle-to-agn-199201.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vehicle to AGN-199201 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vehicle to AGN-199201 (Vehicle to AGN-199201) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurokinin-1 (NK1) receptor antagonist. Area: Pain Management / Neurology.

phase 3 Neurokinin-1 (NK1) receptor antagonist NK1 receptor Pain Management / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Vehicle to AGN-199201 (Vehicle to AGN-199201) — Allergan. AGN-199201 is a selective antagonist of the neurokinin-1 (NK1) receptor that modulates pain signaling in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vehicle to AGN-199201 TARGET	Vehicle to AGN-199201	Allergan	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Akynzeo solution	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
Ramosetron, Aprepitant, Dexamethasone	Ramosetron, Aprepitant, Dexamethasone	Hallym University Medical Center	marketed	5-HT3 antagonist / NK1 antagonist / corticosteroid combination	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
EMEND	EMEND	Merck Sharp & Dohme LLC	marketed	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor (neurokinin-1 receptor)
Fosaprepitant for Injection	Fosaprepitant for Injection	Montefiore Medical Center	marketed	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)
Dexamethasone, Ondansetron, Aprepitant	Dexamethasone, Ondansetron, Aprepitant	Ottawa Hospital Research Institute	marketed	Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist)	Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurokinin-1 (NK1) receptor antagonist class)

Merck Sharp & Dohme LLC · 4 drugs in this class
Organon and Co · 2 drugs in this class
Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vehicle to AGN-199201 — Competitive Intelligence Brief. https://druglandscape.com/ci/vehicle-to-agn-199201. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab